- An experimental oral drug claims to do the work of medications like GLP-1s without losing muscle mass.
- The medication just went through phase 1 clinical trials.
- Doctors explain the new medication and what consumers can expect.
It’s…

It’s…

Newswise — Dementia is a group of disorders that gradually impair memory, thinking and daily functioning. Alzheimer’s disease (AD), the most common form of dementia, affects about 7.2 million Americans aged 65 and…

As temperatures drop, heart attack cases quietly surge – a seasonal reality many people remain unaware of. The cold doesn’t just change the weather outside; it also triggers internal shifts in the body that can place extra strain on the heart….

Acquisition adds eye-tracking-based ADHD medication management tool to HarmonEyes’ growing human performance platform
BETHESDA, Md., Dec. 10, 2025 /PRNewswire/ — HarmonEyes, the…

The most frequent ovarian masses in a pediatric and adolescent population are benign neoplasms and functional cysts, both of which can be causes for ovarian torsion.1 Malignancies in this population are usually germ cell tumors,…

Hypertensive disorders of pregnancy (HDP), encompassing preeclampsia/eclampsia, chronic hypertension, superimposed preeclampsia, and gestational hypertension, affect about 10% of pregnancies worldwide,1 with a prevalence of…

Rectal cancer is a malignant tumour of the digestive system that develops between the junction of the anal canal skin and rectal mucosa and the junction of the rectum and sigmoid colon. Its incidence is rising annually by…

Infective endocarditis (IE) is characterized by inflammation of the heart valves or endocardium caused by various pathogens. Previous research indicated that the incidence of IE ranges from 15 to 60 cases per 1,000,000 individuals,1…

Norovirus – colour-enhanced
Now, a team at The University of Osaka has successfully overcome this long-standing barrier to norovirus research, developing a simple and efficient research system for human norovirus. The researchers published their…